Quick Search
Products bpV(phen) (Potassium bisperoxo (1,10-phenanthroline) oxovanadate (V))
| Catalogue number: | 044615 |
| Size: | 5mg |
| Purity: | >99% (51V-NMR) |
| Alternative names: | Potassium bisperoxo (1,10-phenanthroline) oxovanadate (V) |
| References: | Product Reference: ?Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics: B.I. Posner, et al.; J. Biol. Chem. 269, 4596 (1994) ?Early signaling events triggered by peroxovanadium are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen): C.J. Band, et al.; Mol. Endocrinol. 11, 1899 (1997) ?Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats: J.F. Yale, et al.; Diabetes 44, 1274 (1995) ?In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency: A.P. Bevan, et al.; Am. J. Physiol. 268, E60 (1995) ?A role for tyrosine phosphorylation in both activation and inhibition of the insulin receptor tyrosine kinase in vivo: P.G. Drake, et al.; Endocrinology 137, 4960 (1996) ?BpV (phen) induces apoptosis of RINm5F cells by modulation of MAPKs and MKP-1: L. Rumora, et al.; BBRC 300, 877 (2003) ?Positive regulation of ERK activation and MKP-1 expression by peroxovanadium complex bpV (phen): L. Rumora, et al.; Cell Biol. Toxicol. 20, 293 (2004) ?Peroxovanadium compounds as inhibitors of angiogenesis: C. J. Doillon, et al.; Angiogenesis 3, 361 (1999) ? |
Get the Best Promotions
